

# Girish S Kulkarni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5712065/girish-s-kulkarni-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

171  
papers

2,930  
citations

28  
h-index

48  
g-index

188  
ext. papers

3,679  
ext. citations

4.2  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
171	The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.. <i>Pathology</i> , <b>2022</b> ,	1.6	1
170	Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities. <i>Journal of Urology</i> , <b>2022</b> , 207, 118-126	2.5	0
169	Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 433-433	2.2	2
168	Prostate specific antigen dynamics and prostate cancer risk: A population-based study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 239-239	2.2	
167	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 224-224	2.2	1
166	Prevalence and natural history of non-metastatic castrate resistant prostate cancer: A population-based analysis.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 65-65	2.2	0
165	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.. <i>European Radiology</i> , <b>2022</b> , 1	8	0
164	A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin Unresponsive Nonmuscle-invasive Bladder Cancer. <i>European Urology Open Science</i> , <b>2022</b> , 41, 105-111	0.9	3
163	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. <i>European Urology Focus</i> , <b>2021</b> , 7, 537-545	5.1	5
162	Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada. <i>BMJ Open</i> , <b>2021</b> , 11, e050728	3	1
161	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259272	3.7	0
160	Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study. <i>BJU International</i> , <b>2021</b> , 129, 258	5.6	0
159	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E545-E552	1.2	0
158	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E424-E460	1.2	1
157	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 835.e1-835.e7	2.8	0
156	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , <b>2021</b> , 153, 147-155	1.6	0
155	Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 96-105	6.2	7

154	Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e135-e147	3.3	1
153	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 191.e17-191.e24	2.8	
152	Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 8-9	21.7	3
151	Does prophylactic ureteric stenting at the time of colorectal surgery reduce the risk of ureteric injury? A systematic review and meta-analysis. <i>Colorectal Disease</i> , <b>2021</b> , 23, 1060-1070	2.1	1
150	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. <i>Oncology and Therapy</i> , <b>2021</b> , 9, 21-39	2.7	4
149	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , <b>2021</b> , 81, 286-294	4.2	0
148	Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework. <i>European Urology Focus</i> , <b>2021</b> , 7, 672-682	5.1	0
147	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , <b>2021</b> , 300, 369-379	20.5	5
146	Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study. <i>European Urology</i> , <b>2021</b> , 80, 386-387	10.2	
145	Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level. <i>Journal of Urology</i> , <b>2021</b> , 101097JU00000000000002229	2.5	
144	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , <b>2021</b> , 80, 374-382	10.2	7
143	Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 822-829	6.9	4
142	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 404-410	1.2	1
141	Bladder-sparing treatment options in localized muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 179-188	3.5	1
140	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E373-E382	1.2	3
139	Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3287-3296	4.8	3
138	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 603.e1-603.e7	2.8	7
137	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large, population-based cohort. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 174-181	1.2	5

136	Role of MRI in Staging of Penile Cancer. <i>Journal of Magnetic Resonance Imaging</i> , <b>2020</b> , 51, 1612-1629	5.6	8
135	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 14	6.3	10
134	Modifiable lifestyle behaviours impact the health-related quality of life of bladder cancer survivors. <i>BJU International</i> , <b>2020</b> , 125, 836-842	5.6	2
133	Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5041-5041	2.2	19
132	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , <b>2020</b> , 204, 476-482	2.5	2
131	A Prospective Randomized Controlled Trial of Irrigation "Bag Squeeze" to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , <b>2020</b> , 204, 1012-1018	2.5	8
130	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 622-629	6.2	1
129	Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 850.e9-850.e15	2.8	9
128	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E387-E393	1.2	1
127	Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer-A population-based cohort study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 6946-6953	4.8	3
126	Improving outcomes of radical cystectomy: A call for passive over active regionalization. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, 97-98	1.2	
125	Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E415-E425	1.2	1
124	Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship. <i>World Journal of Urology</i> , <b>2020</b> , 38, 741-746	4	2
123	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
122	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
121	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
120	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
119	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		

118	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
117	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
116	Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study <b>2020</b> , 15, e0236480		
115	Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1910505	10.4	
114	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216255	3.7	15
113	Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matched-cohort study of patients with incident solid-organ malignancies. <i>Cancer</i> , <b>2019</b> , 125, 2886-2895	6.4	24
112	The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 840-847	8.7	18
111	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 88-96	6.7	3
110	Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3877-3885 <sup>20</sup>	3.9	20
109	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 51-60	4	25
108	Reply to Comment on: "The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies". <i>British Journal of Cancer</i> , <b>2019</b> , 121, 195-196	8.7	1
107	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients - A Cross Sectional Study. <i>Urology</i> , <b>2019</b> , 134, 154-162	1.6	4
106	Reply by Authors. <i>Journal of Urology</i> , <b>2019</b> , 202, 325	2.5	
105	Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study. <i>Journal of Urology</i> , <b>2019</b> , 202, 319-325	2.5	1
104	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , <b>2019</b> , E292-E299	1.2	
103	Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada. <i>BMJ Open</i> , <b>2019</b> , 9, e032170	3	1
102	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 119-125	6.7	13
101	Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 275-284	2.7	4

100	Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 10043-10050	3.6	4
99	The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. <i>Cancer</i> , <b>2019</b> , 125, 1050-1059	6.4	14
98	Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1676-1684	7.5	28
97	Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. <i>European Urology</i> , <b>2019</b> , 75, 3-7	10.2	5
96	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 38-45	3.3	18
95	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 230-238	1.2	21
94	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2019</b> , 13, 250-255	1.2	2
93	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 240.e13-240.e20	2.8	6
92	Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 241.e1-241.e6	2.8	1
91	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , <b>2018</b> , 74, 309-321	10.2	40
90	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. <i>Journal of Urology</i> , <b>2018</b> , 199, 906-914	2.5	14
89	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , <b>2018</b> , 199, 1182-1187	2.5	20
88	Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer. <i>Urology</i> , <b>2018</b> , 114, 147-154	1.6	8
87	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. <i>European Radiology</i> , <b>2018</b> , 28, 4281-4287	8	19
86	Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 206-212.e1	3.3	18
85	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , <b>2018</b> , 200, 283-291	2.5	17
84	The Impact of the Choosing Wisely Campaign in Urology. <i>Urology</i> , <b>2018</b> , 116, 81-86	1.6	8
83	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , <b>2018</b> , 73, 834-844	10.2	56

82	Decreasing suicide risk among patients with prostate cancer: Implications for depression, erectile dysfunction, and suicidal ideation screening. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 60-66	2.8	32
81	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 13.e11-13.e18	2.8	3
80	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , <b>2018</b> , 200, 1056-1061	2.5	1
79	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E281-E297	1.2	6
78	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. <i>European Urology</i> , <b>2018</b> , 74, 597-608	10.2	33
77	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, 203-210	1.2	6
76	Statin use and time to progression in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 509-515	6.2	5
75	High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. <i>Oncotarget</i> , <b>2018</b> , 9, 16731-16743	3.3	4
74	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e22144-e22144	2.2	22
73	Medication use and kidney cancer survival: A population-based study. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 1776-1785	7.5	5
72	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. <i>Urology</i> , <b>2018</b> , 113, 138-145	1.6	3
71	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. <i>Journal of Urology</i> , <b>2018</b> , 199, 251-256	2.5	1
70	Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. <i>Oncotarget</i> , <b>2018</b> , 9, 18797-18810	3.3	6
69	Challenges Interpreting Chemoprevention Studies Using Observational Data. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 628-629	2.2	5
68	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients and urologic oncologists perspectives. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E210-E218	1.2	5
67	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1399-1405	8.7	5
66	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 328-334	2.8	16
65	Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 342-348	2.8	9

64	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 52, 105-116	14.4	38
63	Critical appraisal of the application of propensity score methods in the urology literature. <i>BJU International</i> , <b>2017</b> , 120, 873-880	5.6	6
62	Estimating the effect of immortal-time bias in urological research: a case example of testosterone-replacement therapy. <i>BJU International</i> , <b>2017</b> , 120, 584-590	5.6	3
61	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , <b>2017</b> , 120, 76-82	5.6	11
60	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1260-1271	27.4	21
59	Platelet to white blood cell ratio predicts 30-day postoperative infectious complications in patients undergoing radical nephrectomy for renal malignancy. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, E414-E420	1.2	15
58	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 41-46	1.2	7
57	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 167-171	1.2	5
56	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2299-2305	2.2	153
55	Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 661.e7-661.e14 <sup>2,8</sup>	1.2	43
54	The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1273-1286	11.5	21
53	Medication use and kidney cancer risk: A population-based study. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 203-210	7.5	10
52	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 604.e17-604.e24	2.8	2
51	Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis. <i>MDM Policy and Practice</i> , <b>2017</b> , 2, 2381468317709476	1.5	2
50	Diabetes and kidney cancer outcomes: a propensity score analysis. <i>Endocrine</i> , <b>2017</b> , 55, 470-477	4	4
49	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 300-305	3.3	14
48	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , <b>2017</b> , 197, 75-83	2.5	32
47	Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 173-181	1.2	6



46	Vasectomy and risk of prostate cancer: population based matched cohort study. <i>BMJ, The</i> , <b>2016</b> , 355, i5546	5.9	14
45	Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. <i>Urology</i> , <b>2016</b> , 95, 95-102	1.6	15
44	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 207-12	8.7	38
43	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , <b>2016</b> , 93, 77-85	1.6	23
42	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , <b>2016</b> , 195, 307-12	2.5	9
41	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , <b>2016</b> , 69, 933-41	10.2	11
40	Effect of radical prostatectomy surgeon volume on complication rates from a large population-based cohort. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 45-9	1.2	16
39	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 25-30	1.2	15
38	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, E46-80	1.2	39
37	Perioperative outcomes following radical prostatectomy for patients with disseminated cancer: An analysis of the National Surgical Quality Improvement Program database. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 423-429	1.2	0
36	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. <i>BJU International</i> , <b>2016</b> , 117, 401-8	5.6	52
35	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>Urology</i> , <b>2016</b> , 96, 142-147	1.6	3
34	External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. <i>Journal of Urology</i> , <b>2016</b> , 196, 1402-1407	2.5	6
33	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. <i>Pharmacological Research</i> , <b>2016</b> , 113, 468-474	10.2	18
32	Statin use and kidney cancer outcomes: A propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 487.e1-487.e6	2.8	12
31	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. <i>Urology</i> , <b>2016</b> , 97, 145-152	1.6	17
30	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , <b>2016</b> , 196, 1645-1650	2.5	14
29	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 386.e7-13	2.8	28

28	Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. <i>Journal of Urology</i> , <b>2015</b> , 193, 1519-24 <sup>2.5</sup>	75
27	Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. <i>European Urology</i> , <b>2015</b> , 67, 64-70	10.2 66
26	Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, E267-72	1.2 10
25	Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. <i>Urology</i> , <b>2015</b> , 85, 621-7	1.6 21
24	Health-related quality of life in robotic versus open radical prostatectomy. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, 179-87	1.2 8
23	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, E690-704	1.2 53
22	The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. <i>Urology</i> , <b>2014</b> , 84, 1073-80	1.6 1
21	Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. <i>European Urology</i> , <b>2014</b> , 66, 841-8	10.2 46
20	The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy. <i>Journal of Urology</i> , <b>2014</b> , 192, 714-9	2.5 19
19	Is pathology necessary to predict mortality among men with prostate-cancer?. <i>BMC Medical Informatics and Decision Making</i> , <b>2014</b> , 14, 114	3.6 2
18	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 47-52	1.2 10
17	Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. <i>Urology</i> , <b>2014</b> , 83, 81-7	1.6 20
16	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. <i>Lancet Oncology</i> , <b>2014</b> , 15, 223-31	21.7 155
15	A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. <i>European Urology</i> , <b>2014</b> , 66, 406-13	10.2 27
14	Essential experimental steps and estimates of renal carcinoma initiating cells.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11127-11127	2.2
13	Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3069-75	2.2 210
12	Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. <i>European Urology</i> , <b>2013</b> , 64, 421-30	10.2 101
11	Impact of provider volume on operative mortality after radical cystectomy in a publicly funded healthcare system. <i>Canadian Urological Association Journal</i> , <b>2013</b> , 7, 425-9	1.2 9

10	Higher surgeon and hospital volume improves long-term survival after radical cystectomy. <i>Cancer</i> , <b>2013</b> , 119, 3546-54	6.4	76
9	VHL-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4568-4568	2.2	2
8	An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. <i>European Urology</i> , <b>2010</b> , 57, 60-70	10.2	141
7	Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. <i>Cancer</i> , <b>2009</b> , 115, 5450-9	6.4	48
6	Varied definitions of hospital volume did not alter the conclusions of volume-outcome analyses. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 400-7	5.7	29
5	Longer wait times increase overall mortality in patients with bladder cancer. <i>Journal of Urology</i> , <b>2009</b> , 182, 1318-24	2.5	86
4	Effect of healthcare provider characteristics on nodal yield at radical cystectomy. <i>Urology</i> , <b>2008</b> , 72, 128-33		13
3	Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. <i>Cancer</i> , <b>2007</b> , 109, 2432-8	6.4	88
2	Optimal management of high-risk T1G3 bladder cancer: a decision analysis. <i>PLoS Medicine</i> , <b>2007</b> , 4, e28411.6		65
1	Evidence for a biopsy derived grade artifact among larger prostate glands. <i>Journal of Urology</i> , <b>2006</b> , 175, 505-9	2.5	104